Epigenetic system: A pathway to malignancies and a therapeutic target

International Journal of Hematology

Volumn 80, Issue 2, 2004, Pages 103-107

  Nakao, Mitsuyoshi ^a   Minami, Takeshi ^a   Ueda, Yasuaki ^a   Sakamoto, Yasuo ^a   Ichimura, Takaya ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Cancer; Chromatin; Epigenetics; Histone; Therapy

Indexed keywords

HISTONE; TRANSCRIPTION FACTOR;

CANCER CELL; CANCER GENETICS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMATIN; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; GENE ACTIVATION; GENE CONTROL; GENE INACTIVATION; GENE MUTATION; GENE TARGETING; GENOME; ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE;

DNA METHYLATION; EPIGENESIS, GENETIC; GENE SILENCING; GENE THERAPY; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; NEOPLASMS;

EID: 4444362719     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.04052     Document Type: Review

References (34)

1. Grewal SI, Moazed D. Heterochromatin and epigenetic control of gene expression. Science. 2003;301:798-802.
2. Bird AP, Wolffe AP. Methylation-induced repression-belts, braces, and chromatin. Cell. 1999;99:451-454.
3. Nakao M. Epigenetics: interaction of DNA methylation and chromatin. Gene. 2001;278:25-31.
4. Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000;403:41-45.
5. Turner BM. Histone acetylation and an epigenetic code. Bioessays. 2000;22:836-845.
6. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer. 2004;4:143-153.
7. Momparler RL. Cancer epigenetics. Oncogene. 2003;22:6479-6483.
8. Esteller M. Cancer epigenetics: DNA methylation and chromatin alterations in human cancer. Adv Exp Med Biol. 2003;532:39-49.
9. Jones PA. Epigenetics in carcinogenesis and cancer prevention. Ann N Y Acad Sci. 2003;983:213-219.
10. Urnov FD. Chromatin as a tool for the study of genome function in cancer. Ann N Y Acad Sci. 2003;983:5-21.
11. Esteller M. Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg. Clin Immunol. 2003; 109:80-88.
12. Claus R, Lubbert M. Epigenetic targets in hematopoietic malignancies. Oncogene. 2003;22:6489-6496.
13. Wolffe AP, Matzke MA. Epigenetics: regulation through repression. Science. 1999;286:481-486.
14. Fischle W, Wang Y, Allis CD. Binary switches and modification cassettes in histone biology and beyond. Nature. 2003;425:475-479.
15. Jenuwein T. Re-SET-ting heterochromatin by histone methyltransferases. Trends Cell Biol. 2001;11:266-273.
16. Marmorstein R, Roth SY. Histone acetyltransferases: function, structure, and catalysis. Curr Opin Genet Dev. 2001;11:155-161.
17. Rakyan VK, Preis J, Morgan HD, Whitelaw E. The marks, mechanisms and memory of epigenetic states in mammals. Biochem J. 2001;356:1-10.
18. Kingston RE, Narlikar GJ. ATP-dependent remodeling and acetylation as regulators of chromatin fluidity. Genes Dev. 1999;13: 2339-2352.
19. Ng HH, Bird A. DNA methylation and chromatin modification. Curr Opin Genet Dev. 1999;9:158-163.
20. Bestor TH. The DNA methyltransferases of mammals. Hum Mol Genet. 2000;9:2395-2402.
21. Ballestar E, Wolffe AP. Methyl-CpG-binding proteins. Eur J Biochem. 2001;268:1-6.
22. Wade PA. Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum Mol Genet. 2001;10:693-698.
23. Watanabe S, Ichimura T, Fujita N, et al. Methylated DNA-binding domain 1 and methylpurine-DNA glycosylase link transcriptional repression and DNA repair in chromatin. Proc Natl Acad Sci U S A. 2003;100:12859-12864.
24. Ahringer J. NuRD and SIN3 histone deacetylase complexes in development. Trends Genet. 2000;16:351-356.
25. Knoepfler PS, Eisenman RN. Sin meets NuRD and other tails of repression. Cell. 1999;99:447-450.
26. Zhang HS, Dean DC. Rb-mediated chromatin structure regulation and transcriptional repression. Oncogene. 2001;20:3134-3138.
27. Kingston RE, Bunker CA, Imbalzano AN. Repression and activation by multiprotein complexes that alter chromatin structure. Genes Dev. 1996;10:905-920.
28. Satijn DP, Otte AP. Polycomb group protein complexes: do different complexes regulate distinct target genes? Biochim Biophys Acta. 1999;1447:1-16.
29. Borden KL. Pondering the promyelocytic leukemia protein (PML) puzzle: possible functions for PML nuclear bodies. Mol Cell Biol. 2002;22:5259-5269.
30. Zhong S, Salomoni P, Pandolfi PP. The transcriptional role of PML and the nuclear body. Nat Cell Biol. 2000;2:E85-E90.
31. Di Croce L, Raker VA, Corsaro M, et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science. 2002;295:1079-1082.
32. Vigushin DM, Coombes RC. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs. 2002;13:1-13.
33. Reid GK, Besterman JM, MacLeod AR. Selective inhibition of DNA methyltransferase enzymes as a novel strategy for cancer treatment. Curr Opin Mol Ther. 2002;4:130-137.
34. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 2000;92:1210-1216.